J&J can weather new biotech threat: Analyst
Cheaper biotech drugs are headed to the U.S., but one analyst thinks J&J can manage through some of the challenges.
Cheaper biotech drugs are headed to the U.S., but one analyst thinks J&J can manage through some of the challenges.